ATE133866T1 - Antikörper-heterokonjugate zur regulation der lymphozytenaktivität - Google Patents

Antikörper-heterokonjugate zur regulation der lymphozytenaktivität

Info

Publication number
ATE133866T1
ATE133866T1 AT89105907T AT89105907T ATE133866T1 AT E133866 T1 ATE133866 T1 AT E133866T1 AT 89105907 T AT89105907 T AT 89105907T AT 89105907 T AT89105907 T AT 89105907T AT E133866 T1 ATE133866 T1 AT E133866T1
Authority
AT
Austria
Prior art keywords
heteroconjugates
lymphocytes
antibodies
regulation
heteroconjugate
Prior art date
Application number
AT89105907T
Other languages
English (en)
Inventor
Jeffrey A Ledbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Application granted granted Critical
Publication of ATE133866T1 publication Critical patent/ATE133866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89105907T 1988-04-04 1989-04-04 Antikörper-heterokonjugate zur regulation der lymphozytenaktivität ATE133866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US27193488A 1988-11-14 1988-11-14

Publications (1)

Publication Number Publication Date
ATE133866T1 true ATE133866T1 (de) 1996-02-15

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105907T ATE133866T1 (de) 1988-04-04 1989-04-04 Antikörper-heterokonjugate zur regulation der lymphozytenaktivität

Country Status (20)

Country Link
EP (1) EP0336379B1 (de)
JP (1) JP2613106B2 (de)
KR (1) KR100205833B1 (de)
CN (1) CN1058296C (de)
AT (1) ATE133866T1 (de)
AU (1) AU629204B2 (de)
DE (1) DE68925593T2 (de)
DK (1) DK173382B1 (de)
ES (1) ES2083960T3 (de)
FI (1) FI105320B (de)
GR (1) GR3019224T3 (de)
HU (1) HU213576B (de)
IE (1) IE72187B1 (de)
IL (1) IL89823A (de)
MY (1) MY106592A (de)
NO (1) NO178699C (de)
NZ (1) NZ228560A (de)
PT (1) PT90195B (de)
YU (1) YU68589A (de)
ZA (1) ZA892448B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0564735B1 (de) * 1992-04-10 1998-11-18 Thomas Totterman Verfahren zum Nachweis einer CMV-Infektion
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
DK0758394T3 (da) 1994-05-02 2003-03-03 Bernd Groner Bifunktionelt protein, fremstilling og anvendelse
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (de) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Verfahren un Mitteln zur Herstellung von Immunkrankheiten wie Graft-Versus-Host-Krankheit
EP1189635A4 (de) * 1999-06-17 2003-04-23 Univ Vermont Autologe adoptive immuntherapie mit t-zellen oder b-zellenb, welche antigen-spezifisch sensibilisiert wurden
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
DE10034607A1 (de) 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
ES2321701T3 (es) * 2001-10-12 2009-06-10 Schering Corporation Uso de anticuerpos biespecificos que se unen al receptor de activacion fcepsilonri y al receptor de inhibicion ox2ra (cd200ra) para regular respuestas inmunes.
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
WO2021160267A1 (en) * 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (de) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antikörper zur verwendung in einer therapie mit effektorzell-engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (de) * 1984-03-01 1987-07-01 Centocor, Inc. Steigerung der Antigenimmunogenität mittels Antikörper
ATE64622T1 (de) * 1984-04-23 1991-07-15 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.

Also Published As

Publication number Publication date
PT90195B (pt) 1994-06-30
NO891375D0 (no) 1989-03-31
JPH01304356A (ja) 1989-12-07
MY106592A (en) 1995-06-30
IL89823A (en) 1994-07-31
AU3242389A (en) 1989-10-05
YU68589A (en) 1991-10-31
NO891375L (no) 1989-10-05
CN1058296C (zh) 2000-11-08
ZA892448B (en) 1989-12-27
GR3019224T3 (en) 1996-06-30
KR100205833B1 (ko) 1999-07-01
EP0336379A3 (en) 1990-01-31
ES2083960T3 (es) 1996-05-01
EP0336379A2 (de) 1989-10-11
HU213576B (en) 1997-08-28
EP0336379B1 (de) 1996-02-07
KR890015751A (ko) 1989-11-25
FI891528A0 (fi) 1989-03-30
NZ228560A (en) 1991-10-25
IE72187B1 (en) 1997-03-26
HUT51338A (en) 1990-04-28
CN1036988A (zh) 1989-11-08
DE68925593T2 (de) 1996-06-13
NO178699B (no) 1996-02-05
JP2613106B2 (ja) 1997-05-21
IL89823A0 (en) 1989-12-15
FI105320B (fi) 2000-07-31
PT90195A (pt) 1989-11-10
DE68925593D1 (de) 1996-03-21
NO178699C (no) 1996-05-15
FI891528L (fi) 1989-10-05
DK173382B1 (da) 2000-09-11
DK159489D0 (da) 1989-04-03
IE891054L (en) 1989-10-04
AU629204B2 (en) 1992-10-01
DK159489A (da) 1989-10-05

Similar Documents

Publication Publication Date Title
ATE133866T1 (de) Antikörper-heterokonjugate zur regulation der lymphozytenaktivität
ATE137802T1 (de) Monoklonaler antikörper, der mit einer neuen hla- determinante auf mhc-klasse-i-moleküle reagiert, und verfahren zur aktivierung von lymphozyten
DE3380697D1 (en) Monoclonal antibody
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
DE122006000007I1 (de) Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
DE3879000D1 (de) Immunoassaymethode zum auffinden von antikoerpern zu antigenen.
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
FI874047A0 (fi) Monoklonaalisia vasta-ainemolekyylejä, joilla on katalyyttisiä ominaisuuksia omaavia vasta-aineen sitovia kohtia
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
ATE27494T1 (de) Diagnostisches testsystem.
DE3854834D1 (de) Immuntest unter Verwendung von Antigenen, produziert in heterologen Organismen
DE3851221D1 (de) Nichttrennender festphasen-enzymtest.
ATE60445T1 (de) Verfahren und testelement zum auffinden von zellaesionen.
ES546594A0 (es) Un procedimiento para preparar un anticuerpo monocional anti-urocinasa.
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DK673789D0 (da) Monoklonalt antistof, som specifikt binder til kc-48-antigenet i neutrophiler og eosinophiler, samt hybridomocellelinie, som producerer antistoffet
ATE239754T1 (de) An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
NO903788D0 (no) Monoklonalt antistoff mot protein c.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee